Trial · NCT06696248
Carvedilol and Alverine in Portal Hypertension
NCT06696248, Phase 2, Phase 3, Not yet recruiting, Shanghai Changzheng Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carvedilol and Alverine in Portal Hypertension. Trials, record NCT06696248. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06696248
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carvedilol and Alverine in Portal Hypertension
- NCT number
- NCT06696248
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Shanghai Changzheng Hospital
- Conditions
- Hypertension, Portal
- Interventions
- Carvedilol and alverine
- First posted
- 2024-11-20
- Last updated
- 2024-11-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The 24-week response rate | 24 weeks | The response rate to treatment, defined as the percentage of patients with a decrease in HVPG of ≥10% from baseline or a decrease to below 12 mmHg after 24 weeks of treatment. |
| Secondary | Degree of decrease in HVPG compared to baseline HVPG after 24 weeks of treatment. | 24 weeks | |
| Secondary | Incidence of cirrhosis decompensation events during treatment. | 24 weeks | Incidence of cirrhosis decompensation events (including esophageal and gastric variceal bleeding, new-onset ascites/progression of ascites, spontaneous bacterial peritonitis, overt hepatic encephalopathy, acute kidney injury/hepatorenal syndrome, primary liver cancer, etc.) during treatment. |
| Secondary | The 12-week response rate | 12 weeks | The response rate to treatment, defined as the percentage of patients with a decrease in HVPG of ≥10% from baseline or a decrease to below 12 mmHg after 12 weeks of treatment. |
| Secondary | Degree of decrease in HVPG compared to baseline HVPG after 12 weeks of treatment. | 12 weeks | |
| Secondary | Degree of decrease in mean arterial pressure (MAP) compared to baseline MAP after 24 weeks of treatment. | 24 weeks | |
| Secondary | Degree of decrease in heart rate (HR) compared to baseline HR after 24 weeks of treatment. | 24 weeks | |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety assessment] | 24 weeks | The incidence of adverse events, serious adverse events, and adverse events leading to treatment discontinuation after treatment The incidence of adverse events, serious adverse events, and adverse events leading to treatment discontinuation after treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06696248
GET https://conductscience.org/api/trials/v1/NCT06696248/registered